Praluent® is associated with a reduction in major adverse cardiovascular events in the ODYSSEY OUTCOMES CVOT2
Praluent® offers a favourable long-term safety and tolerability profile demonstrated over 5 years in ODYSSEY OUTCOMES1,2
1. Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/8093/smpc. Accessed March 2023
2. Schwartz G, et al. N Engl J Med 2018;379:2097–2107.
Indication, Mechanism of Action and Administration
Expert Hub Videos
Resources include links to videos from Dr Derek Connolly (Consultant Cardiologist, Birmingham UK) discussing topics such as recommended guidance, current clinical trials and peer-2-peer sharing of clinical practice.
Lipid Optimization in ACS patients
In the following video Dr Connolly discusses the evidence for LDL-C causality, the difference between high risk and very high risk patients and the reasons why a post-ACS patient should be screened for lipid optimisation.
The Intensive Lipid-Lowering Approach
In the following video Dr Connolly explains the intensive lipid-lowering therapy approach in high and very high risk ASCVD patients and why this is needed.
Implementing the Intensive Lipid-Lowering Approach
In the following video Dr Connolly discusses implementing the intensive lipid-lowering therapy approach in clinical practice.
Date of Preparation: February 2023
Date of Preparation: March 2023